BrainStorm unveils NurOwn trial design at MDA Clinical and Scientific Conference

BrainStorm announced that it will present a poster outlining the proposed design for a Phase 3b trial of NurOwn in amyotrophic lateral sclerosis, or ALS, at the MDA Clinical and Scientific Conference, on Monday, March 4 between 6-8 p.m. at the Hilton Orlando Hotel, Florida. The design is for a two-part, multicenter, Phase 3b study to assess the efficacy and safety of NurOwn in participants with ALS. Eligible patients will initially enter a 24-week randomized, double-blind, placebo-controlled period, followed by a 24-week open-label extension period. The entry criteria will enroll people living with mild-to-moderate ALS. The primary endpoint will be based on the Revised Amyotrophic Lateral Sclerosis Functional Rating Scale.